Related Experiment Video

Updated: Feb 25, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma

Benjamin J Andrick1, Arpita Gandhi2

  • 11 Geisinger Medical Center, Danville, PA, USA.

The Annals of Pharmacotherapy
|August 6, 2017
PubMed
Abstract

Insights

Olaratumab combined with doxorubicin significantly improves survival for advanced soft tissue sarcoma patients. This novel treatment offers a survival advantage in a rare disease with limited therapeutic options.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced soft tissue sarcoma is a rare disease with limited treatment options.
  • Olaratumab is a human antiplatelet-derived growth factor receptor α monoclonal antibody.

Purpose of the Study:

  • To review and summarize data on olaratumab in combination with doxorubicin for advanced soft tissue sarcoma.
  • To assess the efficacy and safety of olaratumab plus doxorubicin.

Main Methods:

  • Literature search of PubMed (January 2005 to June 2017) using terms: olaratumab, IMC-3G3, advanced soft tissue sarcoma.
  • Prioritization of human studies in English, focusing on trials for advanced soft tissue sarcomas.
  • Analysis of a phase II randomized trial comparing olaratumab plus doxorubicin to doxorubicin monotherapy.

Main Results:

  • The combination therapy showed a response rate of 18.2% versus 11.9% for monotherapy.
  • Median progression-free survival was 6.6 months with combination therapy vs. 4.1 months with monotherapy.
  • Overall survival increased by 11.8 months (26.5 months vs. 14.7 months) with olaratumab plus doxorubicin.

Conclusions:

  • Olaratumab plus doxorubicin is a novel treatment strategy for advanced soft tissue sarcoma.
  • This combination provides a significant survival advantage for patients with this rare disease.
  • The treatment offers a valuable option for a patient population with limited therapeutic choices.
Keywords:
cancerdrug development and approvaloncologypharmacodynamicspharmacokinetics

More Related Videos

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K